2020
DOI: 10.1186/s12991-020-00305-3
|View full text |Cite
|
Sign up to set email alerts
|

Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel

Abstract: Background Management of schizophrenia is sub-optimal in many patients. Targeting negative symptoms, among the most debilitating aspects of schizophrenia, together with positive symptoms, can result in significant functional benefits and dramatically improve quality of life for patients and their carers. Cariprazine, a partial agonist of the dopamine receptors D2/D3 has demonstrated effectiveness across symptom domains in clinical trials, particularly on negative symptoms. Objective To obtain a broader insig… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
34
0
2

Year Published

2021
2021
2024
2024

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 36 publications
(44 citation statements)
references
References 29 publications
2
34
0
2
Order By: Relevance
“…For these reasons, cariprazine is judged to be an advantageous treatment option for patients with schizophrenia and, although treatment decisions need to be made with individual patient characteristics in mind, cariprazine is among the safest antipsychotic treatment options available [90,95]. In most cases, cariprazine-related AEs can be successfully managed by dose reduction; akathisia may be managed by lower doses or a combination of dose reduction and rescue medication [90]. This is a narrative review that has some inherent limitations related to the studies and analyses that were selected for inclusion.…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations
“…For these reasons, cariprazine is judged to be an advantageous treatment option for patients with schizophrenia and, although treatment decisions need to be made with individual patient characteristics in mind, cariprazine is among the safest antipsychotic treatment options available [90,95]. In most cases, cariprazine-related AEs can be successfully managed by dose reduction; akathisia may be managed by lower doses or a combination of dose reduction and rescue medication [90]. This is a narrative review that has some inherent limitations related to the studies and analyses that were selected for inclusion.…”
Section: Discussionmentioning
confidence: 99%
“…Although predominant positive symptoms may be the focus of clinical attention during an acute exacerbation of schizophrenia, addressing negative symptoms and cognitive symptoms is additionally important [ 90 ]. Across a spectrum of presenting symptom scenarios, cariprazine is considered a drug of choice for treating patients with schizophrenia and acute positive symptoms, first episode psychosis, predominant negative symptoms, and metabolic syndrome [ 90 ]. Once acute symptoms are stabilized, long-term treatment of schizophrenia is required to ensure symptom control and prevent relapse [ 91 ].…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…If the weight is placed on the long-term efficacy and tolerability, cariprazine may become one of the first-line medications in schizophrenia, not only for prominent negative symptoms, but also for relatively severe positive symptoms (9). An overlap of at least 2-3 weeks is usually recommended in clinical practice when switching from other antipsychotics to cariprazine, in order to avoid a dopaminergic, antihistaminergic and/or muscarinic rebound (9). This case series presents three young adults with persistent negative symptoms during treatment with an atypical antipsychotic, administered in stable doses within the therapeutic range and for at least 4 weeks, prior to the cariprazine switch.…”
Section: Introductionmentioning
confidence: 99%